Trial Profile
A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2018
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SONET
- Sponsors Janssen
- 18 Jan 2018 Results of pooled post-hoc analysis assessing impact of pharmacokinetic interaction between simeprevir and concomitant medications by using data from nine studies (SONET, OPTIMIST-1, OPTIMIST-2, COMMIT, GALAXY, OSIRIS, IMPACT, PLUTO and SATURN) published in the British Journal of Clinical Pharmacology.
- 17 Apr 2016 Interim results (n=315) presented at The International Liver Congress™ 2016
- 11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.